Development of uterine leiomyoma model using CRISPR/CAS9 genome editing system

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K15610
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Obstetrics and gynecology
• Research Institution: Keio University
• Principal Investigator: MARUYAMA Tetsuo 慶應義塾大学, 医学部(信濃町), 准教授 (10209702)
• Research Collaborator: TAKAO Tomoka 慶應義塾大学, 医学部, 特任助教 (40612429)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 子宮筋腫 / MED12 / CRISPR/CAS9

Outline of Final Research Achievements

Uterine myometrial cells contained a small but significant amount of stem-like cells immediately after isolation from human myometrial tissues. The number of the stem-like cells, however, decreased considerably when they are cultured in vitro. Instead of myometrial stem-like cells, we introduced MED12 mutations, which are observed in approximately 70 % of uterine leiomyomas, into human myometrium cells using CRISPR/CAS9 system, and analyzed hormone-dependent cell proliferation and collagen expression. Preliminary data showed that MED12 mutation did not affect cell growth but tended to induce collagen expression. In vivo leiomyoma model system is under development.

Free Research Field

生殖内分泌、婦人科腫瘍